Compare PSEC & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PSEC | CRVS |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | N/A | 2016 |
| Metric | PSEC | CRVS |
|---|---|---|
| Price | $2.60 | $14.43 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $2.50 | ★ $28.20 |
| AVG Volume (30 Days) | ★ 3.8M | 1.1M |
| Earning Date | 05-07-2026 | 03-12-2026 |
| Dividend Yield | ★ 21.51% | N/A |
| EPS Growth | N/A | ★ 48.04 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.45 | $2.54 |
| 52 Week High | $4.06 | $26.95 |
| Indicator | PSEC | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 47.84 | 44.63 |
| Support Level | $2.52 | $12.95 |
| Resistance Level | $2.82 | $18.73 |
| Average True Range (ATR) | 0.08 | 1.02 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 64.40 | 39.62 |
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests mainly in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.